Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) on November 21, 2014. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction occurred at a price of $46.40 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Points
- Verify the specific number of ADSs allocated to connected persons: 4 ADSs to Dr K Slaoui (connected person of Dr M Slaoui).
- Confirm the transaction date of November 21, 2014, and the execution price of $46.40 per ADS.
- Note that this filing relates to the GSK 401K plan revaluation and does not reflect broader corporate financial performance.